EnVision Summit 2023: The challenges of tube shunts for glaucoma in pediatric eyesFebruary 17th 2023
During a presentation at the EnVision Summit Ophthalmology 2023 at El Conquistador Resort in Puerto Rico, Elena Bitrian, MD, outlines the challenges that surgeons are confronted with surgically in pediatric eyes, including the limited working space and palpebral fissure, axial length, and avoidance of the thin sclera and shallow scleral pass.
Angiogenesis 2023: Reversing the tides of AMD with drug targeting mitochondria to improve photopic visionFebruary 10th 2023
In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 meeting hosted by Bascom Palmer Eye Institute, Baruch Kupperman, MD, PhD, detailed research in which investigators evaluated risuteganib for safety and effectiveness in patients with dry AMD.
Angiogenesis 2023: Visual functional loss in geographic atrophyFebruary 10th 2023
In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.
Angiogenesis 2023: Ophthalmic artery angioplasty to treat age-related macular degenerationFebruary 10th 2023
In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.
CLOSE study offers updated surgical classification for treating large full-thickness macular holesFebruary 6th 2023
According to investigators, a new proposed classification for large and extra-large full-thickness macular holes is based on the surgical results achieved with different surgical techniques
Glaucoma 360: Hypotension and glaucoma progressionFebruary 4th 2023
Ruth Williams, MD, explained the importance of hypotension in glaucoma and its potential as a modifiable risk factor at the 27th annual Glaucoma Symposium during Glaucoma 360 at the Westin St. Francis San Francisco on Union Square.
Glaucoma 360: Drug targets and reduces episcleral venous pressure in glaucomaFebruary 3rd 2023
Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.
Researchers find link between articles published before ophthalmology residency, future career pathJanuary 14th 2023
A study was conducted with the goal of evaluating a correlation between the number of peer-reviewed publications published before a residency and the subsequent peer-reviewed publications or career choices of doctors who graduated from an Ophthalmology residency program.